SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-048405
Filing Date
2023-04-21
Accepted
2023-04-21 16:15:36
Documents
13
Period of Report
2023-04-18
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2313427d1_8k.htm   iXBRL 8-K 32232
  Complete submission text file 0001104659-23-048405.txt   252656

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20230418.xsd EX-101.SCH 3314
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20230418_def.xml EX-101.DEF 27169
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20230418_lab.xml EX-101.LAB 36768
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20230418_pre.xml EX-101.PRE 25791
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2313427d1_8k_htm.xml XML 5185
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 23836544
SIC: 2834 Pharmaceutical Preparations